Patents Assigned to Merck
  • CHEMICALLY DEFINED MEDIA FOR THE GROWTH OR DETECTION OF MICROORGANISMS
    Publication number: 20180355304
    Abstract: The present invention relates to chemically defined culture medium comprising at least one osmoprotectant compound and at least one fatty acid for the detection of a broad range of microorganisms.
    Type: Application
    Filed: November 8, 2016
    Publication date: December 13, 2018
    Applicants: Merck Patent GmbH, Universite de Strasbourg, Centre National de la Recherche Scientifique
    Inventors: Renaud CHOLLET, Antoine GILLMANN, Didier LIEVREMONT, Marie-Claire LETT
  • PYRAZOLOPYRIMIDINE PDE9 INHIBITORS
    Publication number: 20180354955
    Abstract: The present invention is directed to pyrazolopyrimidine compounds which may be useful as therapeutic agents for the treatment of disorders associated with phosphodiesterase 9 (PDE9). The present invention also relates to the use of such compounds for treating cardiovascular and cerebrovascular diseases, such as hypertension, chronic kidney disease and heart failure, and neurological and psychiatric disorders, such as schizophrenia, psychosis or Huntington's disease, and those associated with striatal hypofunction or basal ganglia dysfunction.
    Type: Application
    Filed: June 6, 2018
    Publication date: December 13, 2018
    Applicant: Merck Sharp & Dohme Corp.
    Inventors: Ashok ARASAPPAN, Jason M. COX, John S. DEBENHAM, Zhuyan GUO, Jiafang HE, Zahid HUSSAIN, Zhong LAI, Derun LI, Dongfang MENG, Subharekha RAGHAVAN, Sriram TYAGARAJAN
  • HOMOBISPIPERIDINYL DERIVATIVES AS LIVER X RECEPTOR BETA AGONISTS, COMPOSITIONS AND THEIR USE
    Publication number: 20180354901
    Abstract: In its many embodiments, the present invention provides certain substituted bispiperidinyl compounds of the Formula (I): and pharmaceutically acceptable salts thereof, wherein ring A, ring B, R1, R2, R3, L, R4, X, Z, Li, Q and R5 are as defined herein. The novel compounds of the invention, and pharmaceutically acceptable compositions comprising a compound thereof, are useful as Liver X-? receptor (LXR?) agonists, and may be useful for treating or preventing pathologies related thereto. Such pathologies include, but are not limited to, inflammatory diseases and diseases characterized by defects in cholesterol and lipid metabolism, such as Alzheimer's disease.
    Type: Application
    Filed: November 29, 2016
    Publication date: December 13, 2018
    Applicant: Merck Sharp & Dohme Corp.
    Inventors: Michael T. Rudd, David Jonathan Bennett, Jenny Wai, Zhaoyang Meng
  • Immobilized ketoreductases and process for making and using immobilized ketoreductase
    Patent number: 10150959
    Abstract: The invention is directed to immobilized ketoreductases and methods of making and using them. Enzymes are protein molecules which serve to accelerate the chemical reactions of living cells (often by several orders of magnitude). Without enzymes, most biochemical reactions would be too slow to even carry out life processes. Enzymes display great specificity and are not permanently modified by their participation in reactions. Since they are not changed during the reactions, enzymes can be cost effectively used as catalysts for a desired chemical transformation.
    Type: Grant
    Filed: March 12, 2014
    Date of Patent: December 11, 2018
    Assignee: Merck Sharp & Dohme Corp.
    Inventors: Matthew D. Truppo, Hongmei Li, Johannah R. Moncecchi, Hallena Strotman
  • Liquid crystalline medium
    Patent number: 10150917
    Abstract: The present invention relates to a liquid-crystalline medium based on a mixture of polar compounds having negative dielectric anisotropy (??), which is distinguished by the fact that it has a value for the ratio ?1/?n2 in the range 6-45 with a clearing point of >60° C. and a ?? of ??2.3. Media of this type are particularly suitable for electro-optical displays having active-matrix addressing based on the ECB, PA LCD, FFS or IPS effect.
    Type: Grant
    Filed: October 23, 2015
    Date of Patent: December 11, 2018
    Assignee: MERCK PATENT GMBH
    Inventors: Melanie Klasen-Memmer, Sabine Schoen
  • Pyrrolidine orexin receptor antagonists
    Patent number: 10150751
    Abstract: The present invention is directed to pyrrolidine compounds which are antagonists of orexin receptors. The present invention is also directed to uses of the compounds described herein in the potential treatment or prevention of neurological and psychiatric disorders and diseases in which orexin receptors are involved. The present invention is also directed to compositions comprising these compounds. The present invention is also directed to uses of these compositions in the potential prevention or treatment of such diseases in which orexin receptors are involved.
    Type: Grant
    Filed: December 14, 2015
    Date of Patent: December 11, 2018
    Assignee: Merck Sharp & Dohme Corp.
    Inventors: Scott D. Kuduk, Nigel Liverton, Yunfu Luo, Jason W. Skudlarek
  • Spirocyclic heterocycle compounds useful as HIV integrase inhibitors
    Patent number: 10150780
    Abstract: The present invention relates to Spirocyclic Heterocycle Compounds of Formula (I): (I) and pharmaceutically acceptable salts thereof, wherein A, B, X, R1, R2, R3 and R4 are as defined herein. The present invention also relates to compositions comprising at least one Spirocyclic Heterocycle Compound, and methods of using the Spirocyclic Heterocycle Compounds for treating or preventing HIV infection in a subject.
    Type: Grant
    Filed: December 4, 2015
    Date of Patent: December 11, 2018
    Assignee: Merck Sharp & Dohme Corp.
    Inventors: Thomas H. Graham, Mark W. Embrey, Abbas Walji, Sherman T. Waddell
  • NOVEL PROCESSES FOR MAKING SUBSTITUTED QUINAZOLINE COMPOUNDS USING HYDROGEN BONDING CATALYSTS
    Publication number: 20180346429
    Abstract: Disclosed herein is a novel process for preparing substituted quinazoline compounds of formula (I) using a hydrogen bonding catalyst.
    Type: Application
    Filed: November 18, 2016
    Publication date: December 6, 2018
    Applicant: Merck Sharp & Dohme Corp.
    Inventors: Cheol K. Chung, Guy R. Humphrey, Zhijian Liu, Mark McLaughlin, Yingju Xu, Younong Yu
  • METHOD FOR PREPARING ANTIBODIES HAVING IMPROVED PROPERTIES
    Publication number: 20180346951
    Abstract: The present invention is directed to methods and compositions for the production of Fc-containing polypeptides having improved properties and comprising mutations at positions 243 and 264 of the Fc region.
    Type: Application
    Filed: June 13, 2018
    Publication date: December 6, 2018
    Applicant: Merck Sharp & Dohme Corp.
    Inventors: Terrance A. Stadheim, Dongxing Zha
  • SYSTEM AND METHOD FOR PRESENTING PRODUCT-SPECIFIC CONTENT ON A CLIENT DEVICE BASED ON A SCANNED BARCODE
    Publication number: 20180349974
    Abstract: A system and method for presenting product-specific content on a client device, such as a smart cellphone, tablet, or laptop computer, based on a scanned DataMatrix barcode. A DataMatrix barcode is read by an optical scanner attached to the client device and an application recognizes and parses the data encoded in the DataMatrix barcode to obtain a unique alphanumeric identifier. The unique identifier is transmitted to a digital content server via a data communications network and used by the digital content server to retrieve product-specific content created and maintained on the digital content server by a content management system. The product-specific content, if found on the server, is transmitted to the client device and presented on an output device in accordance with a predefined presentation template.
    Type: Application
    Filed: November 15, 2016
    Publication date: December 6, 2018
    Applicant: Merck Sharp & Dohme Corp.
    Inventors: Debashis DUTTA, Ifat SCHILLER
  • OPPOSITE PH-SALT GRADIENTS FOR IMPROVED PROTEIN SEPARATIONS
    Publication number: 20180346510
    Abstract: The present invention relates to a method for an improved preparative separation of proteins, particularly monoclonal antibodies (mAB) from its associated charge variants (e. g. acidic and basic monomers), glycosylation variants, and/or soluble size variants (e. g. aggregates, monomers, ? fragments, ¾ fragments, antigen binding fragments (Fab) and crystallisable fragments (Fc).
    Type: Application
    Filed: October 28, 2016
    Publication date: December 6, 2018
    Applicant: MERCK PATENT GMBH
    Inventor: Matthias JOEHNCK
  • A METHOD FOR EARLY DETECTION AND IDENTIFICATION OF MICROBIAL-COLONIES, APPARATUS FOR PERFORMING THE METHOD AND COMPUTER PROGRAM
    Publication number: 20180349671
    Abstract: The present invention is directed to a method for detection of microbial colonies on a surface, comprising the steps of obtaining one or a plurality of digital images I0, I1, I2, I3, I4 of the surface, said digital images I0, I1, I2, I3, I4 being represented by at least two-dimensional matrices of pixel values, calculating a statistical noise distribution based on at least one of the digital images I0, applying the statistical noise distribution calculated in the calculation step to the one or the plurality of digital images I0, I1, I2, I3, I4, and detecting an object of interest as a candidate for a microbial colony based on deviation of pixel values from the noise distribution.
    Type: Application
    Filed: August 17, 2016
    Publication date: December 6, 2018
    Applicants: MERCK PATENT GMBH, UNIVERSITE DE STRASBOURG, CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUE (CNRS)
    Inventors: Marine BOUTHILLON, Luc FELDEN, Ola AHMAD, Christophe COLLET
  • MONOLITHIC SORBENTS HAVING A METAL CLADDING
    Publication number: 20180348174
    Abstract: The invention relates to monolithic sorbents which are clad with tubes made of metal. The metal cladding can be applied directly to the monolithic sorbents by cold forming. This enables very mechanically stable cladding of the monolithic sorbents with minimal dead space.
    Type: Application
    Filed: October 28, 2016
    Publication date: December 6, 2018
    Applicant: Merck Patent GmbH
    Inventors: Karin CABRERA, Klaus KREHER, Gisela JUNG
  • Liquid crystalline medium
    Patent number: 10144870
    Abstract: The present invention relates to a liquid-crystalline medium based on a mixture of polar compounds having negative dielectric anisotropy (??), which is distinguished by the fact that it has a value for the ratio ?1/?n2 in the range 6-45 with a clearing point of >60° C. and a ?? of ??2.3. Media of this type are particularly suitable for electro-optical displays having active-matrix addressing based on the ECB, PA LCD, FFS or IPS effect.
    Type: Grant
    Filed: November 8, 2016
    Date of Patent: December 4, 2018
    Assignee: Merck Patent GmbH
    Inventors: Melanie Klasen-Memmer, Sabine Schoen
  • Factor XIa inhibitors
    Patent number: 10143681
    Abstract: The present invention provides a compound of Formula I and pharmaceutical compositions comprising one or more said compounds, and methods for using said compounds for treating or preventing thromboses, embolisms, hypercoagulability or fibrotic changes. The compounds are selective Factor XIa inhibitors or dual inhibitors of Factor XIa and plasma kallikrein.
    Type: Grant
    Filed: August 21, 2017
    Date of Patent: December 4, 2018
    Assignee: Merck Sharp & Dohme Corp.
    Inventors: Dong-Ming Shen, Rongze Kuang, Puneet Kumar, Joseph L. Duffy, Cheng Zhu, Amjad Ali, Meng Yang, John S. Debenham
  • Nargenicin compounds and uses thereof as antibacterial agents
    Patent number: 10144741
    Abstract: The present invention relates to novel nargenicin related compounds which can inhibit DnaE and have antibacterial, particularly antimycobacterial activity against Mycobacterium tuberculosis. The present invention also relates to method for inhibiting growth of mycobacterial cells as well as a method of treating mycobacterial infections by Mycobacterium tuberculosis by administering an antimycobacterially effective amount of nargenicin or a nargenicin-related compound and/or their pharmaceutically acceptable salts.
    Type: Grant
    Filed: March 2, 2018
    Date of Patent: December 4, 2018
    Assignee: Merck Sharp & Dohme Corp.
    Inventors: Katherine Young, David B. Olsen, Sheo B. Singh, Jing Su, Robert R. Wilkening, James M. Apgar, Dongfang Meng, Dann Parker, Mihir Mandal, Lihu Yang, Ronald E. Painter, Qun Dang, Takao Suzuki
  • CO-AGONISTS OF THE GLUCAGON AND GLP-1 RECEPTORS
    Publication number: 20180339017
    Abstract: Co-agonists of the glucagon and GLP-1 receptors are described.
    Type: Application
    Filed: December 5, 2016
    Publication date: November 29, 2018
    Applicant: Merck Sharp & Dohme Corp.
    Inventors: Anandan Palani, Paul E. Carrington, Antonello Pessi, Armin Lahm, Elisabetta Bianchi, Anna Demartis
  • FACTOR XIA INHIBITORS
    Publication number: 20180339977
    Abstract: The present invention provides a compound of Formula (I) and pharmaceutical compositions comprising one or more said compounds, and methods for using said compounds for treating or preventing thromboses, embolisms, hypercoagulability or fibrotic changes. The compounds are selective Factor XIa inhibitors or dual inhibitors of Factor XIa and plasma Kallikrein.
    Type: Application
    Filed: October 24, 2016
    Publication date: November 29, 2018
    Applicant: MERCK SHARP & DOHME CORP.
    Inventors: Jiayi Xu, Amjad Ali, Wei Zhou, Ying-Duo Gao, Scott D. Edmondson, Eric Mertz, Santhosh F. Neelamkavil, Weiguo Liu, Wanying Sun, Dong-Ming Shen, Bart Harper, Cheng Zhu, Thomas Bara, Yeon-Hee Lim, Meng Yang
  • BIARYL MONOBACTAM COMPOUNDS AND METHODS OF USE THEREOF FOR THE TREATMENT OF BACTERIAL INFECTIONS
    Publication number: 20180339983
    Abstract: The present invention relates to biaryl monobactam compounds of Formula I: and pharmaceutically acceptable salts thereof, wherein X, Y, Z, A1, Q, M, W, RX and Rz are as defined herein. The present invention also relates to compositions which comprise a biaryl monobactam compound of the invention or a pharmaceutically acceptable salt thereof, and a pharmaceutically acceptable carrier. The invention further relates to methods for treating a bacterial infection comprising administering to the patient a therapeutically effective amount of a compound of the invention, either alone or in combination with a therapeutically effective amount of a second beta-lactam antibiotic.
    Type: Application
    Filed: December 12, 2016
    Publication date: November 29, 2018
    Applicant: Merck Sharp & Dohme Corp.
    Inventors: Haifeng Tang, Weiguo Liu, Fa-Xiang Ding, Wanying Sun, Yi Zang, Weidong Pan, Anthony Ogawa, Linda Brockunier, Xianhai Huang, Hongwu Wang, Rudrajit Mal, Tesfaye Biftu, Min Park, Yan Guo, Jinlong Jiang, Helen Y. Chen, Christopher W. Plummer
  • LIQUID CRYSTAL MEDIUM
    Publication number: 20180340121
    Abstract: The invention relates to a liquid-crystalline medium based on a mixture of polar compounds having positive dielectric anisotropy, characterised in that it comprises one or more compounds of the formula I in a total concentration of ?40%, in which the parameters have the meanings indicated in claim 1, and to the use of the liquid-crystalline medium for electro-optical purposes, in particular in liquid-crystal light valves for lighting devices for motor vehicles, and to liquid-crystal light valves which comprise this medium and lighting devices for motor vehicles which contain such liquid-crystal light valves.
    Type: Application
    Filed: October 5, 2016
    Publication date: November 29, 2018
    Applicant: MERCK PATENT GMBH
    Inventors: Michael WITTEK, Dagmar KLASS